D.C. biotech Vanda Pharmaceuticals acquires AnaptysBio’s drug for rare skin disorder
D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...
Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
AnaptysBio, Vanda announce exclusive global license agreement for Vanda
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, ...
Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development program.
Today12d
Walmart gets a new logo and people are talking. Here's why
Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...
News Channel Nebraska14d
Circadian Rhythm Sleep Treatment Market is Projected to Reach a Size of US$ 1.23 Billion at a CAGR of 4.7% by 2034
Leading Players Driving Innovation in the Circadian Rhythm Sleep Treatment Market Key players in that circadian rhythm sleep treatment market are Vanda Pharmaceuticals, Inc., Akeda Pharmaceutical ...
FOX 40 WICZ TV14d
Circadian Rhythm Sleep Treatment Market is Projected to Reach a Size of US$ 1.23 Billion at a CAGR of 4.7% by 2034
Leading Players Driving Innovation in the Circadian Rhythm Sleep Treatment Market Key players in that circadian rhythm sleep treatment market are Vanda Pharmaceuticals, Inc., Akeda Pharmaceutical ...
ETF Daily News18d
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at StockNews.com
NASDAQ:VNDA opened at $4.36 on Monday. The company has a market cap of $254.23 million, a P/E ratio of -15.57 and a beta of 0.77. Vanda Pharmaceuticals has a 52-week low of $3.46 and a 52-week ...
Nasdaq18d
Vanda Pharmaceuticals Inc. Common Stock (VNDA) Earnings
Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...